AMR Innovation Mission
Welcome

Dr Ruth McKernan CBE FMedSci
Chair of the UK BioIndustry Association

Antimicrobial Resistance (AMR) – what we know

Over/inappropriate use (healthcare/agriculture) of antibiotics (1940s ++)
AMR already causes >700,000 per year globally. But this is set to become much worse

AMR could become the leading cause of mortality globally, overtaking cancer
Significant direct economic burden (healthcare)
Significant indirect cost burden due to lost productivity, long term health impact, carers etc.

What have we learned from Covid-19

- Health security is now a priority across the world.
- The number of people in hospital and the duration of their stay is critical
- The COVID-19 pandemic has highlighted concerns about AMR. Resistance is now understood
- AMR as a slow pandemic which has huge implication to public and global health
- There is increased use of antibiotics for secondary infections/surgery

Three elements to the solution

How to approach the problem

- Prevention
  - Willingness to change behaviour
  - Public health guidance

- Diagnosis
  - test for the presence or absence of a bacterial infection can dramatically cut overuse
  - Quickly match pathogen to optimal existing treatment
  - surveillance of drug resistance
  - Data and global monitoring

- New Therapeutics

The AMR therapeutic landscape

Innovation is stalled?

The broken business model has made investment hard

Volume of sales is low

New products are kept in reserve to limit the rise of resistance

Pricing is low

Pricing policy compares new drugs with old & cheap generic drugs

R&D costs are inevitably higher than the return on investment

Why SMEs are key players?

SMEs hold 80% of AMR product portfolio



A whole ecosystem of European SMEs focusing on AMR

Source: Deborah O'Neil CEO Novacta, Board member of BioIndustry Association, BEAM

Innovation and partnership

The Future